Amyris, Inc. (AMRS) Q3 2020 Earnings Conference Call November 5, 2020 9:00 AM ETCompany ParticipantsHan Kieftenbeld - Chief Financial OfficerJohn Melo - ...

Amyris, Inc. (AMRS) Q2 2015 Earnings Conference Call August 6, 2015 4:30 PM ETExecutivesPeter DeNardo - Director, IR and Corporate CommunicationsJohn Melo - ...

Amyris CEO John Melo. Bloomberg Finance . When John Melo decided to leave BP 14 years ago to join synthetic biology company Amyris, it was set to be the next big thing in biofuels.But the idea ...

Amyris would have to meet the quotas Melo had presented or lose credibility. Coming from the petroleum industry, Melo saw those volumes as laughably small. But this was a failure of comprehension.

The Bay Area's latest motor fuel factory looks like a microbrewery run by Ph.D.s. Men in white lab coats tend gleaming metal vats filled with yeast and sugar. The air inside the converted ...

(RTTNews) - Amyris, Inc. (AMRS), a synthetic biotechnology company, said on Monday that John Melo has resigned as Chief Executive Officer with immediate effect. Subsequently, the company has ...

John Melo, Amyris CEO, joined Yahoo Finance Live to discuss the company's first-quarter earnings report and why the company is teaming up with Ingredion.

EMERYVILLE, Calif., Nov. 19, 2019 /PRNewswire/ -- Today, the American Diabetes Association has announced that John Melo, President and CEO of Amyris, Inc. (Nasdaq:AMRS) a science and technology ...

On the same call, Melo told investors not to expect the company to produce as much product as it had previously promised. Amyris had said that in 2012 it would produce 40 to 50 million liters of ...

President and CEO of Amyris Inc (30-Year Financial, Insider Trades) John Melo (insider trades) sold 95,115 shares of AMRS on 07/07/2021 at an average price of $15.53 a share.

Melo also pointed out that because Amyris isn't producing ethanol (an alcohol) in Brazil but a hydrocarbon ... Melo said that the company could produce 600 to 800 gallons of fuel per acre.

Amyris Biotechnologies was launched in 2003 by Jay Keasling, professor of Chemical Engineering and Bioengineering at UC Berkeley and the director of the Berkeley Center for Synthetic Biology. For some ...